時間軸調整にて、信用組の振るいも順調に推移し、今回も調整終盤の拾い場を経て、予定通りに面白くなりましたね。笑。 更なる成長の黎明期、中長期の成長戦略も着実に進み、次なる展開・進捗が楽しみですね。笑。 0705山師さん@トレード中 (ワッチョイWW a711-2eP2)2017/12/15(金) 18:02:29.57ID:Z8mOq1xm0 幼稚な株価はいつまで続くんですか? 0706山師さん@トレード中 (ササクッテロロ Spc7-2eP2)2017/12/15(金) 18:02:42.31ID:mgPvfHs0p 幼稚な株価はいつまで続くんですか? 0707山師さん@トレード中 (ワッチョイ 538e-od5V)2017/12/15(金) 18:05:30.13ID:hgaX9KcQ0 ※C&EN: LOOK BACK AT 2007. C&EN steps back in time to look at research advances from a decade ago. December 18, 2017 Volume 95 Issue 49
"G PROTEIN-COUPLED RECEPTOR STRUCTURES AIDED DRUG DESIGN" A decade after a key structural analysis, scientists have a better understanding of the pharmaceutically important family of receptor proteins.
G protein-coupled receptors, or GPCRs, are the largest family of human proteins, with over 800 members. They reside within cell membranes, receiving molecular signals from outside the cell and translating them into signals that influence cellular pathways inside the cell. ・・・ Chris Tate of MRC Laboratory of Molecular Biology and coworkers had earlier used point mutations to stabilize GPCRs without disrupting the proteins’ conformations or functions. The researchers, including Gebhard Schertler, obtained a GPCR structure with the method in 2008. Heptares Therapeutics later obtained rights to that method. Now called StaR, this approach has helped researchers obtain a number of GPCR structures. ・・・ The benefits of GPCR structural information continue to grow. ・・・ Crystal structures also helped Heptares design the GPCR-based drug candidate AZD4635, which AstraZeneca is testing to treat cancer.
“The past 10 years have seen dramatic improvements in our ability to solve X-ray structures of GPCRs and utilize these for drug design,” says Fiona Marshall, director and chief scientific officer of Heptares. ・・・
https://cen.acs.org/articles/95/i49/look-back-at-2007.html#Reversing-Rett-syndrome-in-mice-gave-hope-for-treatments0708山師さん@トレード中 (アウアウカー Sa6f-wk6b)2017/12/15(金) 18:18:54.56ID:r+D3cLfZa>>707 キターーーーーーーー! 0709山師さん@トレード中 (アウアウカー Sa6f-wk6b)2017/12/15(金) 18:21:17.72ID:r+D3cLfZa 10700で売ってくれd(>_< ) 0710山師さん@トレード中 (バッミングク MM42-MwI9)2017/12/15(金) 19:18:49.20ID:S1T/hzDKM>>708 死ねクソ 0711山師さん@トレード中 (アウアウカー Sa6f-wk6b)2017/12/15(金) 19:56:03.53ID:r+D3cLfZa>>710 じゃあ、10800で売ってくれd(>_< ) 0712山師さん@トレード中 (ワッチョイ afcd-vdC7)2017/12/15(金) 21:39:27.89ID:izlGeEgY0 こんな嘘ばかりのスレ取り消せ。 クソボケが 、アホクソボケカスが。 根性無しのカスの集まりが。 どうせ何もできんのやろが? カスはカスらしく黙っとらんかい!クソボケ! 何なんじゃアホが。この根性無しのクズが。 クソボケクズ。クズの集まりじゃねえか。 ポンコツのクソドアホが。ボンクラだろがてめえら。 はっきり言っといてやるよ。 てめえらなんか、何一つ怖くないわ、 このクズ以下のポンコツボンクラが。 0713山師さん@トレード中 (ペラペラ SD52-61v0)2017/12/15(金) 21:40:41.30ID:LrDkvziLD 以上、ポンコツボンクラからの遺言でした。 0714山師さん@トレード中 (ワッチョイ 9797-iaxY)2017/12/15(金) 22:20:34.73ID:DKjc7R8S0 17日にサイエンスZEROでクライオやるんだよね 0715山師さん@トレード中 (ブーイモ MM63-KR2E)2017/12/15(金) 23:59:07.18ID:jUhlOtzIM>>705>>706 これって、、、 0716山師さん@トレード中 (オイコラミネオ MM6e-Hxqa)2017/12/16(土) 00:05:45.10ID:Ev0BP688M 見ちゃダメ🙅‍♂️ 0717山師さん@トレード中 (ワッチョイ 9797-iaxY)2017/12/16(土) 02:10:13.35ID:eGKEU/gN0 ビットコイン→ラクオリアと来ていよいよ皆死んだか 0718山師さん@トレード中 (ワッチョイ 538e-od5V)2017/12/16(土) 06:03:02.90ID:czhhD5/S0 ※Heptares_HP Publications: Added, 2 Title. (12/15up) ・"Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.": (Nature Reviews Drug Discov. 2017 Sep;16(9):787-810.) ・"A monoclonal antibody raised against a thermo-stabilised β1-adrenoceptor interacts with extracellular loop 2 and acts as a negative allosteric modulator of a sub-set of β1-adrenoceptors expressed in stable cell lines.": (Biochem Pharmacol. 2017 Nov 2;147:38-54.)
※HeptaresTL 5時間前:Ten years of advances in GPCR structure-based drug discovery: C&EN Looks back at 2007. (12/15) 0719山師さん@トレード中 (ワッチョイ 538e-od5V)2017/12/16(土) 06:03:56.72ID:czhhD5/S0 ※Journal Med: Current Information for Doctors: "Recommendation on the use of dual bronchodilation for majority symptomatic COPD patients". (12/15) December 15, 2017 At the end of November, Novartis announced positive results from the FLASH study, which evaluated the safety and efficacy of a direct conversion to patients with moderate to severe COPD from salmeterol / fluticasone to indacaterol / glycopyrronium (Ultibro Breezhaler). The GOLD Report recommends the use of dual bronchodilation for majority symptomatic COPD patients and new data supports this recommendation. The first randomized controlled trial FLASH for the direct conversion of LABA / ICS (salmeterol / fluticasone) to Ultibro Breezhaler shows improved lung function in symptomatic patients with moderate to severe COPD. Furthermore, German DACCORD Registry data also provide positive results for direct conversion to indacaterol / glycopyrronium from everyday practice. ・・・ These findings corroborate the current GOLD report, which recommends the use of dual bronchodilation for the majority of symptomatic COPD patients regardless of the risk of exacerbation, and limits the use of ICS-containing therapies to specific types of patients; including patients who continue to exacerbate on LABA / LAMA treatment or who, e.g. have the findings of an asthma COPD overlap. Evidence from everyday clinical practice: Close to clinical practice, the open-label CRYSTAL study, in which symptomatic patients with moderate COPD from their previous therapy (LABA + ICS, LABA / ICS, LABA, LAMA ) directly responded to indacaterol / Glycopyrronium were switched. Here once again a superior improvement in lung function as well as a relief of respiratory distress (according to Transitional Dyspnoe Index) in the patients. The data from the DACCOR Register come directly from everyday clinical practice in Germany. Currently published results also support the recommendations of the GOLD report regarding escalation and de-escalation of COPD therapy. For example, dual bronchodilation should be considered in patients who are symptomatic of bronchodilator monotherapy or LABA / ICS. The data also support the use of LABA / LAMA as the preferred maintenance therapy for symptomatic COPD patients. Furthermore, the analysis provides first practical experience for the de-escalation of LABA / LAMA / ICS to LABA / LAMA. Overall, patients benefited from a one-year follow-up to exacerbations and health status (as measured by the COPD Assessment Test) from a direct switch to dual bronchodilation with indacaterol / glycopyrronium. 0720山師さん@トレード中 (ワッチョイ 1231-pIkr)2017/12/16(土) 08:18:15.03ID:Dm0OJTIl0 楽天の貸株金利が上がって0.25%になったね 一番高いのはGMOの1% 0721山師さん@トレード中 (ワッチョイ 8369-WcAR)2017/12/16(土) 13:06:08.50ID:7e6Zz0Nb0 今からでもこんなとこ損切ってサンバイオへ行けば損失取り戻せるよ サンバは5000円になる! 0722山師さん@トレード中 (スププ Sd32-61v0)2017/12/16(土) 13:49:22.94ID:4EtrV1QQd スレ削除の需要が高まってきてる 0723山師さん@トレード中 (スッップ Sd32-61v0)2017/12/16(土) 17:23:26.16ID:ctOF115Cd じゃあ来るな 0724山師さん@トレード中 (ワッチョイW de97-xqRd)2017/12/16(土) 21:57:56.13ID:wIYPZYkz0 ふと思ったんだけど 一時金って分割で毎年貰った方が良かったんじゃ? 0725山師さん@トレード中 (ワッチョイ 538e-od5V)2017/12/17(日) 07:31:23.86ID:31eJg76w0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 Heptares Approach Extends well Beyond our Growing Pipeline. UK be Relocating to the Cambridge Area in "July 2018." ・・・ ※MiNA: "Innovate UK" Awards Grant: Exciting New Area of Research in Collaboration to "LGC LINK". Grant of up to Approximately 400,000 will Support. (11/2) ※Pluristem: Quarterly Report: Japan NewCo: The Parties have Agreed to Extend the Deadline to Enter into a Definitive Agreement Until December 31, 2017. (11/7) ※ALS Journal: "Metabotropic Glutamate Receptor Type 5 (mGlu5: HTL14242) Plays a Key Role in Glial Activation in the SOD1G93A Mouse Model of MND." (11/7) ※SOSEI:MiNA社、Boehringer Ingelheim社と線維性肝疾患の新治療法開発でライセンス契約締結。契約一時金や研究資金に加え、最大総額307百万ユーロのマイルストン受領予定。(11/8) ※SOSEI:レビー小体型認知症患者を対象とするHTL0018318の日本における臨床開発開始。提携契約を主要な認知症を追加承認取得するため改定。2018年Ph2 POC試験開始予定。(11/9) ※SOSEI第2四半期決算:研究開発費(94.6%は英国)増加。開発促進のための臨床開発並びにトランスレーショナル医療の拡大・拡張へ向けた取組み。毎年平均3品目化合物を臨床入り。(11/9) ※SOSEI第2四半期説明会資料:自社開発(自社での上市・販売)進捗 M1DLB, mGlu5。パイプライン開発進捗状況を更新。"AD4635のPh.1の進捗は良好、年内にP1bへの移行を予定"。(11/9up) ※AstraZeneca Q3 2017 Results, update Clinical Trials: AZD4635 (A2AR): Solid Tumours and Non-Small Cell Lung Cancer: Phase 1: "Data Anticipated: 2018". (11/9) ※米国特許出願(MiNA):Albumin Production and Cell Proliferation. (11/9公開) ※国際特許出願(AstraZeneca):Inhibitors of Protease-Activated Receptor-2. (Inventors: AstraZeneca R&D & Heptares). (11/16公開) ※LeadXpro: LeadXpro Scientists Chart the Future of Structure Based Drug Discovery. Serial Crystallography with the New XFEL Technology. A2A(Heptares) was Employed. (11/27) ※SOSEI:ウルティブロへ治療薬切り替え後のCOPD患者肺機能を有意に改善。Seretideから切り替えで肺機能が改善し、良好な忍容性を有する新データ(FLASH)が得られた。(11/28) ※ClinicalTrials: Study to Compare QVM149 and Free Triple Combination (salmeterol/ fluticasone+ tiotropium): Changed, Protocol: Similar→"Non-Inferior" (11/28update) ※Pluristem: Peer-Reviewed Article Published on PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue. "Data Supports Advanced PLX-PAD Clinical." (11/29) ※ClinicalTrials: AZD4635, Phase 1, Estimated Study Completion Date Changed: "August 23, 2019", Number of Patients Changed: 51→"156". (11/29update) ※中国COPD新薬市場の進展:2018年には中国市場に参入予定。Ultibroも2017年5月に中国で上市申請を行い、来年後半以降、COPD市場全体に新たな変化が起こることが予想されます。(12/8) ※Pluristem: Granted Manufacturer Authorization and GMP Certification by Israel’s Ministry of Health. "The Approval Supports the Readiness of Manufacturing Capabilities." (12/12) ※中国COPDインダカテロール/グリコピロニウム化合物:CFDA薬物登録の進捗状況が「承認」に変更され、国内レビューおよび承認作業の完了に近づいています。(12/12) ・・・ ※SOSEI株主通信 第28期中間決算号:12月予定 ※J.P.Morgan Healthcare Conference, San Francisco: "Attend: Heptares Executive Management Team (Business Development Event)" (2018/1/8-11) ・・・